cas 7752-78-5|| where to buy 5-bromo-2-methylpyrimidine

Nombre del producto:5-bromo-2-methylpyrimidine

IUPAC Name:5-bromo-2-methylpyrimidine

Unidad de embalaje	Stock disponible	Precio($)
CM104177-100g	in stock	Ĳľƿ
CM104177-250g	in stock	ƥǤĲ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Notas adicionales

Verification code*

refresh

: Núm. De CAS :7752-78-5; Fórmula molecular:C5H5BrN2; Punto de fusión:-; Código de sonrisas:CC1=NC=C(Br)C=N1; Densidad:

: Número de catálogo:CM104177; Peso molecular:173.01; Punto de ebullición:; Nº Mdl:MFCD07375143; Almacenamiento:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Voydeya; Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.